Advertisement
Research Article

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

  • Christopher M. O'Connor mail,

    christophe.oconnor@duke.edu

    Affiliation: Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina, United States of America

    X
  • Mona Fiuzat,

    Affiliation: Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina, United States of America

    X
  • Peter E. Carson,

    Affiliation: Division of Cardiology, Department of Veterans Affairs, Washington, District of Columbia, United States of America

    X
  • Inder S. Anand,

    Affiliation: Division of Cardiology, Department of Veterans Affairs, Minneapolis, Minnesota, United States of America

    X
  • Jonathan F. Plehn,

    Affiliation: National Heart, Lung, and Blood Institute, National Institutes of Health, Washington, District of Columbia, United States of America

    X
  • Stephen S. Gottlieb,

    Affiliation: Department of Medicine, University of Maryland, Baltimore, Maryland, United States of America

    X
  • Marc A. Silver,

    Affiliation: Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, Illinois, United States of America

    X
  • JoAnn Lindenfeld,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Alan B. Miller,

    Affiliation: Division of Cardiology, University of Florida Health Sciences Center, Jacksonville, Florida, United States of America

    X
  • Michel White,

    Affiliation: Research Center, Montreal Heart Institute, Montreal, Quebec, Canada

    X
  • Ryan Walsh,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Penny Nelson,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Allen Medway,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • Gordon Davis,

    Affiliation: ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Alastair D. Robertson,

    Affiliation: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America

    X
  • J. David Port,

    Affiliations: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America, ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • James Carr,

    Affiliation: ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Guinevere A. Murphy,

    Affiliation: ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Laura C. Lazzeroni,

    Affiliation: Department of Psychiatry and Behavioral United States of America, Sciences and of Pediatrics, Stanford University, Stanford, California, United States of America

    X
  • William T. Abraham,

    Affiliation: Ohio State University, Columbus, Ohio, United States of America

    X
  • Stephen B. Liggett,

    Affiliation: Center for Personalized Medicine and Genomics, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America

    X
  • Michael R. Bristow

    Affiliations: Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America, ARCA biopharma, Broomfield, Colorado, United States of America

    X
  • Published: October 10, 2012
  • DOI: 10.1371/journal.pone.0044324

About the Authors

Christopher M. O'Connor, Mona Fiuzat
Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina, United States of America
Peter E. Carson
Division of Cardiology, Department of Veterans Affairs, Washington, District of Columbia, United States of America
Inder S. Anand
Division of Cardiology, Department of Veterans Affairs, Minneapolis, Minnesota, United States of America
Jonathan F. Plehn
National Heart, Lung, and Blood Institute, National Institutes of Health, Washington, District of Columbia, United States of America
Stephen S. Gottlieb
Department of Medicine, University of Maryland, Baltimore, Maryland, United States of America
Marc A. Silver
Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, Illinois, United States of America
JoAnn Lindenfeld, Ryan Walsh, Penny Nelson, Allen Medway, Alastair D. Robertson, J. David Port, Michael R. Bristow
Division of Cardiology/Cardiovascular Institute, University of Colorado School of Medicine, Aurora, Colorado, United States of America
Alan B. Miller
Division of Cardiology, University of Florida Health Sciences Center, Jacksonville, Florida, United States of America
Michel White
Research Center, Montreal Heart Institute, Montreal, Quebec, Canada
Gordon Davis, J. David Port, James Carr, Guinevere A. Murphy, Michael R. Bristow
ARCA biopharma, Broomfield, Colorado, United States of America
Laura C. Lazzeroni
Department of Psychiatry and Behavioral United States of America, Sciences and of Pediatrics, Stanford University, Stanford, California, United States of America
William T. Abraham
Ohio State University, Columbus, Ohio, United States of America
Stephen B. Liggett
Center for Personalized Medicine and Genomics, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America

Corresponding Author

Email: christophe.oconnor@duke.edu

Competing Interests

Drs Bristow, Carr, Murphy, and Port and Mr Davis are employees of and own stock or stock options in ARCA biopharma, Inc., which owns the rights to bucindolol. Drs Fiuzat, Liggett, Lindenfeld, and Robertson are consultants of ARCA biopharma. Also, Drs Fiuzat and Liggett own stock or stock options in ARCA biopharma. Drs O'Connor, Carson, Anand, Plehn, Gottlieb, Silver, Miller, White, Lazzeroni, and Abraham and Mr Walsh, Ms Nelson, and Mr Medway have no conflicts to report. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: GD ADR JDP WTA SBL MRB. Performed the experiments: MF RW PN AM SBL. Analyzed the data: CMO PEC ISA JFP SSG MAS JL ABM MW GD ADR LCL MRB. Wrote the paper: MF GAM SBL MRB. Interpreted the data: CMO MF PEC ISA JFP SSG MAS JL ABM MW RW PN AM GD ADR JDP JC GAM LCL WTA SBL MRB. Revised the paper for important intellectual content: CMO MF PEC ISA JFP SSG MAS JL ABM MW GD ADR JDP JC GAM LCL SBL MRB. Contributed reagents/materials/analysis tools, procurement of human hearts: AM.